These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30504508)

  • 1. Associations Between Methotrexate Use and the Risk of Cardiovascular Events in Patients with Elderly-onset Rheumatoid Arthritis.
    Widdifield J; Abrahamowicz M; Paterson JM; Huang A; Thorne JC; Pope JE; Kuriya B; Beauchamp ME; Bernatsky S
    J Rheumatol; 2019 May; 46(5):467-474. PubMed ID: 30504508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs.
    Xie F; Chen L; Yun H; Levitan EB; Curtis JR
    J Rheumatol; 2021 Jun; 48(6):804-812. PubMed ID: 33060309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis.
    Davis LA; Cannon GW; Pointer LF; Haverhals LM; Wolff RK; Mikuls TR; Reimold AM; Kerr GS; Richards JS; Johnson DS; Valuck R; Prochazka A; Caplan L
    J Rheumatol; 2013 Jun; 40(6):809-17. PubMed ID: 23547211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.
    Johnson TM; Sayles HR; Baker JF; George MD; Roul P; Zheng C; Sauer B; Liao KP; Anderson DR; Mikuls TR; England BR
    Ann Rheum Dis; 2021 Nov; 80(11):1385-1392. PubMed ID: 34049859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
    Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
    Lee JL; Sinnathurai P; Buchbinder R; Hill C; Lassere M; March L
    Arthritis Res Ther; 2018 Aug; 20(1):171. PubMed ID: 30086795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy.
    Matsubara H; Kojima T; Kaneko A; Hirano Y; Ishikawa H; Hattori Y; Miyake H; Oguchi T; Takagi H; Yabe Y; Kato T; Ito T; Fukaya N; Kanayama Y; Shioura T; Hayashi M; Fujibayashi T; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Terabe K; Ishiguro N
    J Rheumatol; 2014 Aug; 41(8):1583-9. PubMed ID: 25028370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database.
    Sakai R; Tanaka E; Inoue E; Harigai M
    RMD Open; 2024 Jun; 10(2):. PubMed ID: 38886005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to methotrexate treatment in patients with rheumatoid arthritis referred to hospital.
    de Thurah A; Nørgaard M; Johansen M; Stengaard-Pedersen K
    Scand J Rheumatol; 2010; 39(1):19-25. PubMed ID: 20132066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study.
    Moura CS; Abrahamowicz M; Beauchamp ME; Lacaille D; Wang Y; Boire G; Fortin PR; Bessette L; Bombardier C; Widdifield J; Hanly JG; Feldman D; Maksymowych W; Peschken C; Barnabe C; Edworthy S; Bernatsky S;
    Arthritis Res Ther; 2015 Aug; 17(1):197. PubMed ID: 26235697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
    Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S
    Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
    Ideguchi H; Ohno S; Ishigatsubo Y
    J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts.
    Kiely P; Busby AD; Nikiphorou E; Sullivan K; Walsh DA; Creamer P; Dixey J; Young A
    BMJ Open; 2019 May; 9(5):e028466. PubMed ID: 31061059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
    Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
    J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.
    Wluka A; Buchbinder R; Mylvaganam A; Hall S; Harkness A; Lewis D; Littlejohn GO; Miller MH; Ryan PF
    J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis.
    Bonafede M; Johnson BH; Tang DH; Shah N; Harrison DJ; Collier DH
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1656-63. PubMed ID: 26097194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.
    Kooloos WM; Wessels JA; van der Straaten T; Allaart CF; Huizinga TW; Guchelaar HJ
    Pharmacogenomics; 2010 Feb; 11(2):163-75. PubMed ID: 20136356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.